Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AUPH NYSE:PBH NASDAQ:PCRX NASDAQ:PRNB NASDAQ:XNCR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAUPHAurinia Pharmaceuticals$11.55$12.04$6.55▼$13.54$1.52B1.251.77 million shs971,496 shsPBHPrestige Consumer Healthcare$62.08+0.4%$64.31$60.15▼$90.04$3.06B0.44460,911 shs325,022 shsPCRXPacira BioSciences$22.87+0.4%$25.37$16.00▼$27.64$1.03B0.4494,614 shs246,471 shsPRNBPrincipia Biopharma$100.05$100.05$25.35▼$101.89$3.32B0.86729,676 shsN/AXNCRXencor$14.77-1.2%$9.84$6.92▼$27.24$1.05B0.961.43 million shs1.94 million shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAUPHAurinia Pharmaceuticals0.00%+2.48%-10.40%+33.84%+60.86%PBHPrestige Consumer Healthcare0.00%+1.92%-3.21%-17.99%-13.68%PCRXPacira BioSciences0.00%+2.33%-14.18%+5.93%+37.52%PRNBPrincipia Biopharma0.00%0.00%0.00%0.00%0.00%XNCRXencor0.00%+13.35%+47.26%+64.66%-31.37%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAUPHAurinia Pharmaceuticals$11.55$12.04$6.55▼$13.54$1.52B1.251.77 million shs971,496 shsPBHPrestige Consumer Healthcare$62.08+0.4%$64.31$60.15▼$90.04$3.06B0.44460,911 shs325,022 shsPCRXPacira BioSciences$22.87+0.4%$25.37$16.00▼$27.64$1.03B0.4494,614 shs246,471 shsPRNBPrincipia Biopharma$100.05$100.05$25.35▼$101.89$3.32B0.86729,676 shsN/AXNCRXencor$14.77-1.2%$9.84$6.92▼$27.24$1.05B0.961.43 million shs1.94 million shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAUPHAurinia Pharmaceuticals0.00%+2.48%-10.40%+33.84%+60.86%PBHPrestige Consumer Healthcare0.00%+1.92%-3.21%-17.99%-13.68%PCRXPacira BioSciences0.00%+2.33%-14.18%+5.93%+37.52%PRNBPrincipia Biopharma0.00%0.00%0.00%0.00%0.00%XNCRXencor0.00%+13.35%+47.26%+64.66%-31.37%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAUPHAurinia Pharmaceuticals 2.67Moderate Buy$13.0012.55% UpsidePBHPrestige Consumer Healthcare 2.43Hold$94.8052.71% UpsidePCRXPacira BioSciences 2.43Hold$33.4046.04% UpsidePRNBPrincipia Biopharma 0.00N/AN/AN/AXNCRXencor 2.64Moderate Buy$24.2264.00% UpsideCurrent Analyst Ratings BreakdownLatest PCRX, AUPH, XNCR, PRNB, and PBH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/14/2025XNCRXencorWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025AUPHAurinia PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)10/8/2025PBHPrestige Consumer HealthcareWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)10/8/2025PCRXPacira BioSciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)10/8/2025XNCRXencorCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy10/6/2025XNCRXencorCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$40.009/27/2025AUPHAurinia PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)9/27/2025PBHPrestige Consumer HealthcareWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)9/27/2025PCRXPacira BioSciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)9/27/2025XNCRXencorWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/24/2025PBHPrestige Consumer HealthcareSidotiSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$80.00(Data available from 10/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAUPHAurinia Pharmaceuticals$260.11M5.84$0.31 per share37.45$2.68 per share4.31PBHPrestige Consumer Healthcare$1.14B2.69$5.21 per share11.91$37.04 per share1.68PCRXPacira BioSciences$705.85M1.46$4.32 per share5.30$16.86 per share1.36PRNBPrincipia Biopharma$35.16M94.50N/AN/A$10.95 per share9.14XNCRXencor$146.93M7.17N/AN/A$9.63 per share1.53Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAUPHAurinia Pharmaceuticals$5.75M$0.4326.8620.63N/A23.31%20.06%13.81%11/6/2025 (Estimated)PBHPrestige Consumer Healthcare$214.60M$4.2614.5713.041.9619.02%12.69%6.79%11/6/2025 (Estimated)PCRXPacira BioSciences-$99.56M-$2.78N/A8.90N/A-18.08%13.29%6.61%11/5/2025 (Estimated)PRNBPrincipia Biopharma-$53.79M-$2.09N/AN/AN/AN/A-23.08%-21.11%N/AXNCRXencor-$232.62M-$2.40N/AN/AN/A-121.52%-25.75%-18.19%11/5/2025 (Estimated)Latest PCRX, AUPH, XNCR, PRNB, and PBH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/6/2025Q3 2025AUPHAurinia Pharmaceuticals$0.17N/AN/AN/A$67.70 millionN/A11/6/2025Q2 2026PBHPrestige Consumer Healthcare$1.01N/AN/AN/A$257.14 millionN/A11/5/2025Q3 2025PCRXPacira BioSciences$0.66N/AN/AN/A$182.86 millionN/A11/5/2025Q3 2025XNCRXencor-$0.72N/AN/AN/A$29.73 millionN/A8/7/2025Q1 2026PBHPrestige Consumer Healthcare$1.01$0.95-$0.06$0.95$260.71 million$249.53 million8/6/2025Q2 2025XNCRXencor-$0.78-$0.41+$0.37-$0.41$22.59 million$43.61 million8/5/2025Q2 2025PCRXPacira BioSciences$0.73$0.74+$0.01-$0.11$183.11 million$181.10 million7/31/2025Q2 2025AUPHAurinia Pharmaceuticals$0.17$0.16-$0.01$0.16$64.27 million$70.01 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAUPHAurinia PharmaceuticalsN/AN/AN/AN/AN/APBHPrestige Consumer HealthcareN/AN/AN/AN/AN/APCRXPacira BioSciencesN/AN/AN/AN/AN/APRNBPrincipia BiopharmaN/AN/AN/AN/AN/AXNCRXencorN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAUPHAurinia Pharmaceuticals0.185.234.63PBHPrestige Consumer Healthcare0.554.382.99PCRXPacira BioSciences0.502.381.91PRNBPrincipia BiopharmaN/A17.0117.01XNCRXencorN/A5.345.34Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAUPHAurinia Pharmaceuticals36.83%PBHPrestige Consumer Healthcare99.95%PCRXPacira BioSciences99.73%PRNBPrincipia Biopharma95.54%XNCRXencorN/AInsider OwnershipCompanyInsider OwnershipAUPHAurinia Pharmaceuticals12.20%PBHPrestige Consumer Healthcare1.40%PCRXPacira BioSciences6.40%PRNBPrincipia Biopharma16.01%XNCRXencor4.76%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAUPHAurinia Pharmaceuticals300131.63 million115.57 millionOptionablePBHPrestige Consumer Healthcare54049.21 million48.53 millionOptionablePCRXPacira BioSciences72044.93 million42.06 millionOptionablePRNBPrincipia Biopharma6533.21 millionN/ANot OptionableXNCRXencor28071.32 million67.93 millionOptionablePCRX, AUPH, XNCR, PRNB, and PBH HeadlinesRecent News About These CompaniesStocks Showing Improving Market Leadership: Xencor Earns 83 RS RatingOctober 17 at 9:38 PM | msn.comAberdeen Group plc Grows Stock Position in Xencor, Inc. $XNCROctober 17 at 3:32 AM | marketbeat.comXencor Stock Earns Relative Strength Rating UpgradeOctober 16 at 5:32 PM | msn.comXencor (NASDAQ:XNCR) Earns Sell (D-) Rating from Weiss RatingsOctober 16 at 2:07 AM | americanbankingnews.comXencor (NASDAQ:XNCR) Shares Up 10% - Should You Buy?October 15, 2025 | marketbeat.comXencor Announces Presentation of Initial Phase 1 Dose-Escalation Results of XmAb819 in Clear Cell Renal Cell Carcinoma at the AACR-NCI-EORTC International Conference on ...October 14, 2025 | finance.yahoo.comXencor price target raised to $14 from $12 at BofAOctober 14, 2025 | msn.comXencor slides amid plans for early-stage trial data for kidney cancer drugOctober 14, 2025 | msn.comXencor (NASDAQ:XNCR) Trading Down 13.3% - Should You Sell?October 14, 2025 | marketbeat.comXencor (NASDAQ:XNCR) Receives "Sell (D-)" Rating from Weiss RatingsOctober 14, 2025 | marketbeat.comXencor Announces Presentation of Initial Phase 1 Dose-Escalation Results of XmAb819 in Clear Cell Renal Cell Carcinoma at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsOctober 14, 2025 | businesswire.comXencor Sees RS Rating Rise To 73October 13, 2025 | msn.comAnalysts Offer Predictions for Xencor FY2025 EarningsOctober 12, 2025 | americanbankingnews.comEquities Analysts Issue Forecasts for Xencor FY2025 EarningsOctober 11, 2025 | marketbeat.comXencor (NASDAQ:XNCR) Upgraded at Cantor FitzgeraldOctober 11, 2025 | americanbankingnews.comXencor, Inc. (NASDAQ:XNCR) Receives Consensus Rating of "Moderate Buy" from AnalystsOctober 11, 2025 | americanbankingnews.comXencor, Inc. (NASDAQ:XNCR) Given Average Rating of "Moderate Buy" by AnalystsOctober 11, 2025 | marketbeat.comXencor (NASDAQ:XNCR) Raised to Strong-Buy at Cantor FitzgeraldOctober 10, 2025 | marketbeat.comCantor Fitzgerald Reaffirms Overweight Rating for Xencor (NASDAQ:XNCR)October 8, 2025 | americanbankingnews.comCantor Fitzgerald Forecasts Xencor FY2025 EarningsOctober 7, 2025 | marketbeat.comXencor (NASDAQ:XNCR) Given "Overweight" Rating at Cantor FitzgeraldOctober 6, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePCRX, AUPH, XNCR, PRNB, and PBH Company DescriptionsAurinia Pharmaceuticals NASDAQ:AUPH$11.55 0.00 (0.00%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$11.38 -0.17 (-1.43%) As of 10/17/2025 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.Prestige Consumer Healthcare NYSE:PBH$62.08 +0.27 (+0.44%) Closing price 10/17/2025 03:59 PM EasternExtended Trading$62.16 +0.08 (+0.13%) As of 10/17/2025 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.Pacira BioSciences NASDAQ:PCRX$22.87 +0.10 (+0.44%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$22.86 -0.02 (-0.07%) As of 10/17/2025 04:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.Principia Biopharma NASDAQ:PRNBPrincipia Biopharma Inc., a late-stage biopharmaceutical company, focuses on developing novel therapies for immunology and oncology. The company is developing PRN1008, an inhibitor that is in Phase III clinical trial for the treatment of pemphigus, a chronic skin disease, as well as in Phase II clinical trial to treat immune thrombocytopenic purpura. It is also developing PRN2246/SAR442168, an inhibitor, which has completed Phase I clinical trial for treating multiple sclerosis (MS) and other central nervous system (CNS) diseases; PRN1371, a drug candidate that is in Phase I clinical trial for the treatment of solid tumors; and oral small molecule inhibitors of the immunoproteasome. The company has a collaboration agreement with Genzyme Corporation to develop relapsing and progressive MS and other diseases of the CNS. Principia Biopharma Inc. was incorporated in 2008 and is headquartered in South San Francisco, California.Xencor NASDAQ:XNCR$14.77 -0.18 (-1.20%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$14.78 +0.02 (+0.10%) As of 10/17/2025 05:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom Inks OpenAI Deal: Why It's A Huge Win for AVGO Stock Institutions Are Fueling CrowdStrike’s Next Leg Higher This AI Chip Giant Could Be the Market’s Next Big Winner Microsoft & NVIDIA Unveil GB300 Supercomputer as AI Race Heats Up This Less-Hyped Tech Stock Could Be the Key to the Next AI Wave Archer Buys Rival's Patent Treasure Trove in Strategic Move Prologis Stock Surges: Why the Rally May Continue Intel's Turnaround Hits Hyperspeed With A New 52-Week High Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
